ERBB2 and breast carcinoma: In breast cancer, two poly(ADP-ribose) polymerase (PARP) inhibitors, olaparib (OlympiAD trial) and talazoparib (EMBRACA trial), have been approved to treat germline BRCA carriers with metastatic HER2-negative breast cancer [125,126].